BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer

Stephanie Cabarcas-Petroski 1,2* and Laura Schramm 2,3*

1 Department of Biology, Beaver Campus, Pennsylvania State University, Monaca, PA 15061, USA; smc1088@psu.edu
2 Department of Biology, St. John’s University, Queens, NY 11439, USA
3 Correspondence: schramml@stjohns.edu

Simple Summary: Breast cancer accounts for 30% of all new cancer diagnoses in the United States. The most common type of breast cancer is invasive breast cancer. A hallmark trait of breast cancer is uncontrolled cell growth due to genetic alterations. TFIIIB-mediated RNA polymerase III transcription is specifically deregulated in human cancers. The TFIIIB BDP1 subunit is not well characterized in human cancer. The objective of this study was to analyze publicly available clinical cancer datasets to determine if BDP1 alterations correlate with clinical outcomes in available breast cancer datasets. BDP1 copy number and expression negatively correlate with breast cancer outcomes, including stage, grade, and mortality.

Abstract: TFIIIB is deregulated in a variety of cancers. However, few studies investigate the TFIIIB subunit BDP1 in cancer. BDP1 has not been studied in breast cancer patients. Herein, we analyzed clinical breast cancer datasets to determine if BDP1 alterations correlate with clinical outcomes. BDP1 copy number (n = 1602; p = 8.03 \times 10^{-7}) and mRNA expression (n = 130; p = 0.002) are specifically decreased in patients with invasive ductal carcinoma (IDC). In IDC, BDP1 copy number negatively correlates with high grade (n = 1992; p = 2.62 \times 10^{-19}) and advanced stage (n = 1992; p = 0.005). BDP1 mRNA expression also negatively correlated with high grade (n = 55; p = 6.81 \times 10^{-4}) and advanced stage (n = 593; p = 4.66 \times 10^{-4}) IDC. Decreased BDP1 expression correlated with poor clinical outcomes (n = 295 samples): a metastatic event at three years (p = 7.79 \times 10^{-7}) and cancer recurrence at three years (p = 4.81 \times 10^{-7}) in IDC. Decreased BDP1 mRNA correlates with patient death at three (p = 9.90 \times 10^{-6}) and five (p = 1.02 \times 10^{-6}) years. Both BDP1 copy number (n = 3785; p = 1.0 \times 10^{-14}) and mRNA expression (n = 2434; p = 5.23 \times 10^{-6}) are altered in triple-negative invasive breast cancer (TNBC). Together, these data suggest a role for BDP1 as potential biomarker in breast cancer and additional studies are warranted.

Keywords: BDP1; TFIIIB; BRF2; BRF1: RNA polymerase III; breast cancer

1. Introduction

In the United States (U.S.), breast cancer accounts for 30% of new cancer diagnoses in women [1]. Breast cancer incidence rates continue to increase approximately 0.5% each year, with breast cancer being the leading cause of death in women aged 20 to 59 [1]. Breast cancers are classified by site and if the breast cancer is invasive or non-invasive [2]. Approximately 287,850 new cases of invasive breast cancer (IBC) and 51,400 cases of non-invasive breast cancer are expected to be diagnosed in 2022 [3]. The most common types of breast cancer include ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC) [2]. Together, IDC and ILC account for 90% of all IBC; DCIS is the most common non-invasive breast cancer diagnosed [4].

Many cancers, including breast cancer, are driven by genetic and epigenetic alterations leading to deregulated cell proliferation. In eukaryotes, cell proliferation is regulated, in
part, by three RNA polymerases (pol) [5]. RNA pol I transcribes genes encoding ribosomal RNA required by ribosomes; RNA pol II transcribes mRNA encoding proteins and some small untranslated RNA molecules involved in RNA processing [5]. RNA pol III transcribes untranslated RNA molecules involved in processing and translation [5]. Together, RNA pol I and pol III regulate the biosynthetic capacity of a cell.

It is well-established that RNA pol III transcription is deregulated in various human cancers [6,7]. The initiation of RNA pol III transcription requires TFIIIB [5,8]. Two forms of TFIIIB have been identified in higher eukaryotes [8,9]. Accurate transcription initiation from gene-internal RNA pol III promoters requires a TFIIIB complex containing TBP, BRF1, and BDP1 [8,9]. Transcription from gene-external RNA pol III promoters requires a TFIIIB complex containing TBP, BRF2, and BDP1 [8,9]. TFIIIB activity is inhibited by tumor suppressors, including p53 [10,11], PTEN [12–14], BRCA1 [15], the retinoblastoma protein (Rb) [11], and the Rb family members p107 and p130 [16]. The oncogenes MAP kinase ERK and MYC [11,17] stimulate TFIIIB activity in vitro. The TFIIIB subunits TBP [18–20], BRF1 [21–24], and BRF2 [6,22,25–32] have begun to be studied in specific human cancers. For example, BRF2 has been classified as a novel proto-oncogene in human cancers [6,27,31,32]. However, studies that determine whether BDP1 is altered in human cancers and clinically relevant are limited. A study implicating BDP1 in prostate cancer was performed in a PTEN-null prostate cancer cell line [14]. Somatic frameshift mutations in BDP1 have been identified in colorectal cancer, n = 98, but clinical outcome data were not reported in the commentary [33]. Recently, BDP1 expression has been correlated with clinical outcomes in non-Hodgkin lymphoma [34]. Together, these recent studies suggest a detailed analysis of BDP1 alterations in human cancers is warranted.

The objective of this study was to analyze publicly available clinical cancer datasets to determine if BDP1 alterations correlate with clinical outcomes in available breast cancer datasets. Herein, we report that BDP1 copy number (n = 1602; p = 8.03 × 10^{-5}) and mRNA expression (n = 130; p = 0.002) are specifically decreased in patients with invasive ductal carcinoma (IDC). In IDC, BDP1 copy number negatively correlated with high grade (n = 1992; p = 2.62 × 10^{-19}) and advanced stage (n = 1992; p = 0.005). BDP1 mRNA expression also negatively correlated in high grade (n = 55; p = 6.81 × 10^{-4}) and advanced stage (n = 593; p = 4.66 × 10^{-4}) IDC. Interestingly, decreased BDP1 expression correlated with clinical outcomes (n = 295 samples): a metastatic event at three years (p = 7.79 × 10^{-7}) and cancer reoccurrence at three years (p = 4.81 × 10^{-7}) in patients with invasive breast cancer (IBC). Decreased BDP1 mRNA correlates with patient death at three (p = 9.90 × 10^{-6}) and five (p = 1.02 × 10^{-6}) years. BDP1 copy number decreased in triple-negative invasive breast cancer (TNBC) (n = 3786; p = 1.04 × 10^{-21}). Both BDP1 copy number (n = 3785; p = 1.0 × 10^{-14}) and mRNA expression (n = 2434; p = 5.23 × 10^{-6}) are altered in TNBC. Additionally, BDP1 mRNA expression is increased by the breast cancer chemotherapeutics doxorubicin (13.146-fold increase; p = 4.43 × 10^{-4}), etoposide (9.703-fold increase; p = 8.15 × 10^{-4}), fluorouracil (9.468-fold increase; p = 0.005), and bortezomib (1.831-fold increase; p = 0.002) in well-studied breast cancer cell lines [35,36]. Taken together, these data suggest a role for BDP1 alterations in invasive breast cancer. Additional studies are warranted to determine if BDP1 may be a novel target for breast cancer therapy.

2. Materials and Methods

BDP1 copy number and mRNA expression in breast cancer were analyzed using microarray datasets available in the Oncomine™ Research Edition Platform [37,38]. The Oncomine™ Research Premium Edition Platform is a cancer microarray database and web-based data-mining platform [37,38] containing 729 cancer datasets (91,866 samples) and was queried, January 2020–January 2022, to determine if BDP1 alterations correlate with clinical outcomes [37,38]. The Oncomine™ Research Premium Edition Platform datasets are log-transformed, median centered per array, and standard deviation normalized to one per array; statistical tests conducted both as two-sided for differential expression analysis and one-sided for specific over- and under-expression analysis [37,38].
For whole study analysis, \( p \)-values were corrected for multiple comparisons by the method of false discovery rates (FDR) \[37,38\].

For BDP1 expression analyses in specific datasets, cut-off values, sample numbers, and \( p \)-values are indicated in the figure legends. The Oncomine\textsuperscript{TM} Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization. Public datasets queried are noted below, with hyperlinks to the available datasets and study descriptions (Table 1) and are cited in figure legends.

**Table 1.** Datasets used in study. Hyperlinks to datasets are provided.

| Dataset | Study Description and Link to Dataset | Reference |
|---------|---------------------------------------|-----------|
| Barretina | The Cancer Cell Line Encyclopedia (CCLE), consisting of 947 human cancer cell lines encompassing 36 tumor types, used genomic technology platforms for characterization. Of the 947 human cancer cell lines, 56 cell lines represented breast cancer types. Link to dataset: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36138, accessed January 2020–January 2022. | [39] |
| Curtis 2 | A total of 1992 primary breast tumors were studied using an integrated genomic and transcriptomic analysis. Overall, 997 of the 1992 represent a discovery set of primary tumors and 995 of the 1992 tumors were a validation set from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). Link to dataset: http://www.ebi.ac.uk/ega/studies/EGAS00000000083, accessed January 2020–January 2022. | [40] |
| Esserman | The I-SPY 1 trial (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis) collected invasive breast cancers from patients with tumor size >3 cm and patients with T4 or inflammatory disease. Patients were evaluated for specific biomarker profiles to understand chemotherapy response and recurrence-free survival. Then, 130 out of the total 221 patients eligible for analysis were used in this report. Link to dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22226, accessed January 2020–January 2022. | [41] |
| Kao | This study analyzed 327 breast cancer samples for gene expression profiles resulting in identification of molecular subtypes with distinct molecular and clinical characteristics. Link to dataset: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20685, accessed January 2020–January 2022. | [42] |
| Miyake | This study, primary breast cancer patients, stage II-III, treated with neoadjuvant 5-fluorouracil/epirubicin/cyclophosphamide (P-FEC) were analyzed (\( n = 123 \)). Link to dataset: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32646, accessed January 2020–January 2022. | [43] |
| Nickeleit | MCF-7 breast cancer cells were treated with bortezomib, a proteasome inhibitor. Link to dataset: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8565, accessed January 2020–January 2022. | [36] |
| Nikolosky | A total of 191 breast tumors (154 primary tumors and 37 breast cancer cell lines) were characterized for copy number alterations. Link to dataset: https://portals.broadinstitute.org/tcga/home, accessed January 2020–January 2022. | [44] |
| TCGA | The Cancer Genome Atlas Program (TCGA) characterized over 20,000 primary cancer and normal samples for 33 cancer types. For this study, we utilized the invasive ductal carcinoma datasets (\( n = 1602 \)). Link to dataset: http://tcga-data.nci.nih.gov/tcga/, accessed January 2020–January 2022. | [45–47] |
| Troester | This study utilized ME16C and HME-CC cells (basal-like hTERT-immortalized HME cell lines), MCF-7 and ZR-75-1 cells to identify genes that showed differential expression between DOX- and 5FU-treatment to determine if there were toxicant-specific gene expression patterns. Link to dataset: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1647, accessed January 2020–January 2022. | [35] |
| vandeVijver | A total of 295 primary invasive breast carcinomas were analyzed for gene-expression signatures associated with poor prognosis or good prognosis. Breast dataset invasive breast carcinoma. Link to dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2845, accessed January 2020–January 2022. | [48] |

3. Results

We queried all breast cancer datasets housed in the Oncomine\textsuperscript{TM} Research Platform (132 datasets, 14,277 samples) \[37,38\] to determine if BDP1 copy number or mRNA expression is altered in breast cancer and if BDP1 alterations correlated with clinical outcomes in breast cancer.
3.1. BDP1 Copy Number and mRNA Expression Is Decreased in IDC

A query of the 132 breast cancer datasets in the Oncomine™ Research Edition Platform [37,38] for BDP1 alterations identified changes in BDP1 copy number and mRNA expression in invasive ductal carcinoma (IDC) in cancer versus cancer histology analysis, Figure 1. Ductal carcinoma is classified as non-invasive ductal carcinoma in situ (DCIS) or invasive ductal carcinoma (IDC). Annually, IDC is the most frequently diagnosed form of breast cancer. BDP1 copy number is significantly decreased in IDC (−1.073-fold change, p = 8.03 × 10−9) in the TCGA breast cancer dataset (n = 1602) [45–47], Figure 1A. The gene rank for BDP1 DNA copy number loss in IDC is in the top 1% (139) of 18,823 measured genes in the TCGA breast dataset [45–47]. Figure 1B demonstrates that BDP1 mRNA expression is significantly decreased in IDC (−1.341-fold change, p = 0.002) in the Esserman breast cancer dataset (n = 130) [41]. The gene rank for BDP1 in IDC is in the top 1% (72) of 19,189 measured genes in the Esserman breast cancer dataset [41].

Figure 1. BDP1 DNA copy number and mRNA expression decrease in invasive ductal carcinoma (IDC). (A) We queried the TCGA breast dataset [45–47], n = 1602 samples, and BDP1 copy number is significantly decreased in IDC (−1.073-fold change), p-value = 8.03 × 10−9. The gene rank for BDP1 DNA copy number loss in IDC is in the top 1% (139) of 18,823 measured genes in the TCGA breast dataset [45–47]. (B) BDP1 mRNA expression is significantly decreased in IDC (−1.341-fold change) when querying the Esserman breast cancer dataset [41], n = 130 samples, p-value = 0.002. The gene rank for BDP1 mRNA expression in IDC is in the top 1% (72) of 19,189 measured genes in the Esserman dataset [41]. Bright blue denotes statistically significant BDP1 changes. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.

3.2. BDP1 Alterations Negatively Correlate in High Grade and Advanced Stage IDC

Copy number alterations of specific genes at specific chromosomes have been demonstrated to correlate with clinical outcomes in breast cancer, including a chromosomal loss in 5q13.2–q15 [49]. BDP1 has been mapped to cytogenetic band 5q13.2 and deletions of chromosome 5q13-13 have been identified in poorly differentiated IDC [50] and deletions of chromosome 5q13-14 have been associated with triple-negative breast cancer (TNBC) and poor prognosis [51]. Thus, we sought to determine if the observed BDP1 alterations in copy number and mRNA expression noted in Figure 1 correlate with IDC grade and stage. We queried the Curtis breast dataset (n = 1992) [40] to determine if changes in BDP1 copy number correlated with IDC grade. Figure 2A demonstrates that decreased BDP1 copy
number negatively correlates with IDC grade, \( p = 2.62 \times 10^{-19} \). BDP1 copy number is also significantly decreased in advanced stage IDC, \( p = 0.005 \), Figure 2B. Next, we examined BDP1 mRNA expression in grade and stage of IDC patients. In Figure 2C, BDP1 mRNA expression is significantly decreased in the Ginestier breast dataset (\( n = 55 \)) [52], and correlates with high grade IDC, \( p = 6.81 \times 10^{-4} \). BDP1 mRNA expression is significantly decreased in the TCGA breast dataset (\( n = 593 \)) [45–47], \( p = 4.66 \times 10^{-4} \). We further analyzed BDP1 expression and breast cancer substage using the GEIPA platform [53], Supplementary Figure S1. We examined TP53, BRCA1, and BRCA2 in the breast cancer substage analysis because these genes are frequently altered in sporadic and hereditary breast cancer. BDP1, BRCA1, and BRCA2 expression were significantly altered, whereas TP53, frequently mutated in breast cancer, was not significantly altered, as shown in Figure 2D. These data suggest BDP1 alterations negatively correlate with grade and stage in IDC patients.

**Figure 2.** BDP1 copy number and mRNA expression negatively correlate with advanced grade and stage in invasive ductal carcinoma (IDC). (A) BDP1 copy number is significantly decreased in the Curtis breast dataset [40], \( n = 1992 \) samples and \( p = 2.62 \times 10^{-19} \). The gene rank for BDP1 under-expression is in the top 1% (66) of 18,823 measured genes in IDC, high grade. Using the same Curtis Breast dataset [40], (B) BDP1 copy number is also significantly decreased in advanced stage IDC, \( p = 0.005 \). The gene rank for BDP1 is in the top 3% (547) of 18,823 measured genes in IDC, advanced stage. (C) BDP1 expression is significantly decreased in the Ginestier breast dataset [52], \( n = 55 \) samples and correlates with high grade IDC, \( p = 6.81 \times 10^{-4} \). The gene rank for BDP1 under-expression is in the top 1% (193) of 19,574 measured genes in IDC, high grade. (D) BDP1 expression significantly decreases in the TCGA breast dataset [45–47], \( n = 593 \) samples and \( p = 4.66 \times 10^{-4} \). The gene rank for BDP1 under-expression is in the top 1% (120) of 20,423 measured genes in IDC, advanced stage. Bright blue denotes statistically significant BDP1 changes. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.
3.3. BDP1 Alterations Negatively Correlate with Clinical Outcomes in IDC

Figure 2 demonstrates that BDP1 copy number and mRNA expression negatively correlate with high grade and advanced stage IDC. Thus, we sought to determine if BDP1 copy number and mRNA expression correlate with clinical outcomes. A query of the vandeVijver breast dataset (n = 295) [48] identified decreases in BDP1 mRNA expression that correlate with clinical outcomes in IBC, Figure 3.

Figure 3. BDP1 alterations negatively correlate with clinical outcomes. Queries of the vandeVijver Breast dataset [48], n = 295 samples, identified significant decreases in BDP1 mRNA expression correlates with clinical outcomes in invasive breast cancer (IBC). (A) Comparison of nonmetastatic and metastatic events, at three years; BDP1 mRNA expression is significantly decreased (−1.115-fold change), p-value = 7.79 × 10^-7; the gene rank is in the top 1% (47) of 14,719 measured genes in IBC. (B) BDP1 mRNA expression is significantly decreased (−1.110-fold change), p-value = 4.81 × 10^-7, in patients with recurring IBC at three years; the gene rank is in the top 1% (82) of 14,719 measured genes. (C) BDP1 mRNA expression is significantly decreased (−1.106-fold change), p-value = 9.90 × 10^-6 in
patients who died at three years; the gene rank is in the top 1% (110) of 14,719 measured genes in IBC.

(D) BDP1 mRNA expression is significantly decreased (−1.125-fold change), \( p = 1.02 \times 10^{-6} \), in patients with IBC and died at five years; the gene rank is in the top 1% (93) of 14,719 measured genes.

(E) BDP1 copy number is decreased (−1.038-fold change), \( p = 1.07 \times 10^{-5} \), in patients with recurring IDC at three years; the gene rank is in the top 4% (611) of 18,823 measured genes in the Curtis breast dataset [40].

(F) BDP1 copy number is decreased (−1.025-fold change), \( p = 1.29 \times 10^{-4} \), in patients with recurring IDC at five years; the gene rank is in the top 5% (921) of 18,823 measured genes in the Curtis breast dataset [40]. Bright blue denotes statistically significant BDP1 changes. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.

Figure 3A compares nonmetastatic and metastatic events at three years. BDP1 mRNA expression is significantly decreased (−1.115-fold change, \( p = 7.79 \times 10^{-7} \)) in patients having a metastatic event at three years. BDP1 mRNA expression is significantly decreased (−1.110-fold change, \( p = 4.81 \times 10^{-7} \)) in patients with recurring IBC at three years, as shown in Figure 3B. Next, we looked at BDP1 alterations and survival at three and five years. In Figure 3C, BDP1 mRNA expression is significantly decreased (−1.106-fold change, \( p = 9.90 \times 10^{-6} \)) in patients who died at three years. BDP1 mRNA expression is significantly decreased (−1.125-fold change, \( p = 1.02 \times 10^{-6} \)) in patients with IBC who died at five years, as shown in Figure 3D. We next sought to determine if BDP1 copy number correlates with clinical outcomes. Figure 3E provides evidence that BDP1 copy number is decreased (−1.038-fold change, \( p = 1.07 \times 10^{-5} \)) in patients with recurring IDC at three years. Additionally, BDP1 copy number is decreased (−1.025-fold change, \( p = 1.29 \times 10^{-4} \)) in patients with recurring IDC at five years, as shown in Figure 3F. Taken together, Figure 3 demonstrates that BDP1 alterations negatively correlate with clinical outcomes. The negative correlation between BDP1 copy number and mRNA expression with clinical outcomes in Figure 3 led us to question whether BDP1 copy number and expression levels correlated with known breast cancer biomarkers and clinical outcomes.

3.4. BDP1 and Steroid Hormone Expression Correlate with Clinical Outcomes

The estrogen receptor (ER) and progesterone receptor (PR) steroid receptors were the first biomarkers classified in breast cancer [54]. ER-negative breast cancers are more likely to be of higher grade; patients tend to have a decreased overall survival depending on menopausal and lymph node status [55]. In postmenopausal women, a negative ER status is associated with recurrence [56]. PR negative breast cancer patients tend to show cancer recurrence or die within the first five years [57]. Thus, we evaluated if BDP1 mRNA expression correlates with steroid receptor expression and clinical outcomes (Figure 4). Fold-change, \( p \)-value, and gene rank are noted in Figure 4 legend. In Figure 4A, we compared BDP1, ER (gene symbol ESR1), and PR (gene symbol PGR) mRNA expression in metastatic breast cancer occurring three-year post-diagnosis. Figure 4A suggests BDP1 expression correlates with steroid receptors’ expression in patients with metastatic IBC. Next, we looked at breast cancer recurrence three years post initial diagnosis, as shown in Figure 4B. BDP1, ER, and PR expression was significantly decreased in patients whose breast cancer reoccurred three years after the initial diagnosis. Further, BDP1, ER, and PGR expression correlated with death after three years (Figure 4C) and five years (Figure 4D). Together, the data in Figure 4 suggest BDP1 expression correlates with expression changes to the PR and ER breast cancer biomarkers, and clinical outcomes.
Figure 4. BDP1, progesterone receptor (PR), and estrogen receptor (ESR1) expression correlated with clinical outcomes. We queried the vandeVijver breast dataset [48], n = 295 samples, for changes in BDP1 and key breast cancer biomarkers (PR and ESR1) expression and clinical outcomes: (A) metastatic event at three years, (B) recurrence at three years, death at three (C) and five (D) years. [40]. Fold-change, p-value, and gene rank of 14,719 measured genes in IBC are denoted. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.

3.5. BDP1 Is Altered in Triple-Negative Breast Cancer (TNBC)

BDP1 mRNA expression correlates with ER and PR mRNA expression in the context of clinical outcomes measured in Figure 4. Approximately 15% of IBC is characterized by low expression of ER, PR, and the human epidermal growth factor receptor 2 (HER2) and is classified as TNBC [58]. TNBC is molecularly diverse and disproportionately affects younger women with poor clinical outcomes [59]. BDP1, PR, and ER expression are significantly decreased in the breast cancer datasets queried and negatively correlate with clinical outcomes, as shown in Figure 4. As a result, we speculated if BDP1 is altered in TNBC. We queried the TNBC breast cancer datasets available in the Oncomine™ Platform to identify BDP1 copy number and mRNA expression alterations in TNBC, as shown in Figure 5. BDP1 copy number is significantly decreased in triple-negative breast cancer, \( p = 1.04 \times 10^{-21}, n = 3785 \) samples across three datasets [40,44,47], as shown in Figure 5A. Approximately 70% of TNBCs has been demonstrated to undergo deletions spanning the long arm of chromosome, including 5q13-14 [51], and BDP1 is located at 5q13.2. BDP1 mRNA expression is decreased in TNBC, \( p = 5.23 \times 10^{-6}, n = 2434 \) samples across three datasets [40,42,43], as shown in Figure 5B. We cannot rule out the possibility that the decreased BDP1 mRNA expression may be due, in part, to the decrease in ER expression. We queried the Eukaryotic Promoter Database (https://epd.epfl.ch, accessed January–February 2022) [60] and identified four putative ER binding sites at −976, −785, −711, and −535, \( p = 0.001 \), in the BDP1 promoter that may regulate BDP1 expression.
Cancers 2022, 13, x FOR PEER REVIEW 9 of 15

Figure 5. BDP1 is altered in triple-negative breast cancer. (A) BDP1 copy number decreased in triple-negative breast cancer, \( p = 1.04 \times 10^{-21} \) (gene rank 74), \( n = 3785 \) samples [40,44,47]. (B) BDP1 expression is decreased in triple-negative breast cancer, \( p = 5.23 \times 10^{-6} \) (gene rank 717), \( n = 2434 \) samples [40,42,43]. The Oncomine® Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.

3.6. BDP1 mRNA Expression Is Increased by Breast Cancer Chemotherapeutics

In this study, we demonstrate BDP1 copy number and mRNA expression decrease in IDC (Figure 1). BDP1 alterations negatively correlate high grade and advanced stage (Figure 2). Additionally, BDP1 alterations negatively correlate with clinical outcomes (Figure 3), correlate with ER and PR expression in IBC (Figure 4), and significantly decrease in TNBC (Figure 5). Together, these data prompted us to determine if available public datasets provide insight into whether BDP1 is a potential therapeutic target in breast cancer. Using Oncomine, we performed a perturbation analysis of breast cancer datasets available to potentially identify chemotherapeutic agents regulating BDP1 mRNA expression. Based on the statistically significant decrease in BDP1 mRNA expression \( (p = 1.04 \times 10^{-21}) \) and significant gene rank (74) in TNBC, across three studies and \( n = 3785 \) samples [40,44,47] (Figure 5), we queried for chemotherapeutics known to be effective in treating TNBC [61–63]. TNBC can be further classified into subtypes, including basal-like TNBC.

We first queried the Troester [35] cell line dataset. We noted that BDP1 mRNA expression is significantly increased \( (p = 4.43 \times 10^{-4}) \) in the basal-like hTERT-immortalized human mammary epithelial (HME) cell line ME16C cells treated with doxorubicin (DOX), as shown in Figure 6A. DOX intercalates into DNA strands, inhibiting DNA topoisomerase II, ultimately inducing apoptosis [64]. Dox-based chemotherapy is one of the common treatments for TNBC but identifying biomarkers capable of predicting whether TNBC patients will respond to DOX remains challenging and ongoing. Recently, it has been demonstrated that DOX inhibits cell proliferation by activating cAMP response element binding protein 3-like 1 (CREB3L1) and that CREB3L1 expression determines DOX sensitivity [65]. A query of the Eukaryotic Promoter Database (https://epd.epfl.ch, accessed January–February 2022) [60] identified three putative CREB3L1 binding sites at −589, −394, and −392, \( p = 0.001 \), in the BDP1 promoter, suggesting a potential mechanism for regulation of BDP1 expression in DOX treated ME16C cells. Figure 6A prompted us to query additional TNBC chemotherapeutics potentially regulating BDP1 expression. BDP1 mRNA expression is significantly increased \( 9.703 \)-fold \( (p = 8.15 \times 10^{-4}) \) in etoposide (ET) treated ME16C cells, as shown in Figure 6B. ET is a chemotherapeutic used to treat TNBC and induces double-stranded DNA breaks [61]. In Figure 6C, we queried for changes to BDP1 mRNA expression in response to fluorouracil treatment (5-FU), one of the oldest chemotherapeutics used to treat breast cancer using the Troester [35] cell line dataset. ME16C cells treated with 5-FU increased BDP1 mRNA expression \( 9.468 \)-fold, gene rank 127 (top 1%), \( p = 0.005 \). In Figure 6D, we queried for changes to BDP1 mRNA expression in response to bortezomib treatment of MCF-7 cells in the Nickeleit [36] cell line dataset.
Bortezomib is a proteasome inhibitor inducing apoptosis in TNBC cell lines by down-regulating CIP2A-dependent p-Akt, demonstrated to be associated with more aggressive breast cancers [63]. BDP1 mRNA expression 1.831-fold, gene rank 138 (top 1%), \( p = 0.002 \), as shown in Figure 6D. It is well established that the PI3K/Akt/mTOR/S6K pathway regulates RNA polymerase III transcription through TFIIIB [13]. However, it has not been determined if the TFIIIB subunit BDP1 is directly regulated by the PI3K/Akt/mTOR/S6K pathway. Together, Figures 5 and 6 suggests a larger study of potential alterations in BDP1 expression in TNBC patients is warranted.

**Figure 6.** Breast cancer chemotherapeutics increase BDP1 mRNA expression. A query of the Troester [35] and Nickeleit [36] cell line datasets for BDP1 mRNA expression in ME16C and MCF7 cells in response to (A) doxorubicin, (B) etoposide, (C) fluorouracil, or (D) bortezomib treatment. \( p \)-values, fold-change, and gene rank are indicated in the figure. Detailed methods are provided in the published papers by Troester et al. [35] and Nickeleit et al. [36]. Bright blue denotes statistically significant BDP1 changes. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI, USA) was used for analysis and visualization.

**4. Discussion**

To the best of our knowledge, this is the first study to correlate BDP1 alterations with clinical outcomes in breast cancer. The functional genomics approach to investigating BDP1 alterations in breast cancer is significant. The BDP1 gene encodes a 2250 amino acid protein with a predicted molecular weight of 250 kilodaltons and characterized in vitro characterization [8,9]. Early in vitro characterization of BDP1 has achieved using truncated forms of BDP1 to elucidate structural and RNA pol III promoter binding information [66]. The size
of BDP1 has hindered researchers from working on full-length BDP1 in vitro to the extent in vitro characterization has progressed on other TFIIIB subunits. Advances in microarray and RNA-sequencing have provided a more focused approach to studying TFIIIB activity in cancer, specifically with these analyses performed using clinical samples [6,25,34,67].

Herein, we report that BDP1 copy number \( (n = 1602; p = 8.03 \times 10^{-9}) \) and mRNA expression \( (n = 130; p = 0.002) \) are specifically decreased in patients with invasive ductal carcinoma (IDC), as shown in Figure 1. BDP has been cytogenetically mapped to 5q13.2, and deletions of chromosome 5q13-23 have been identified in poorly differentiated IDC [50]. Chromosome 5q13-14 have been associated with triple-negative breast cancer (TNBC) and poor prognosis [51]. Hence, we examined if BDP1 alterations correlated with clinical outcomes in breast cancer. BDP1 copy number negatively correlated with high grade \( (n = 1992; p = 2.62 \times 10^{-19}) \) and advanced stage \( (n = 1992; p = 0.005) \), as shown in Figure 2. In Figure 2, we also demonstrate that BDP1 mRNA expression negatively correlated with high grade \( (n = 55; p = 6.81 \times 10^{-4}) \) and advanced stage \( (n = 593; p = 4.66 \times 10^{-4}) \) IDC. Decreased BDP1 expression correlated with clinical outcomes, as shown in Figure 3 \( (n = 295) \): a metastatic event at three years \( (p = 7.79 \times 10^{-7}) \) and cancer reoccurrence at three years \( (p = 4.81 \times 10^{-7}) \) in patients with invasive breast cancer. Decreased BDP1 mRNA correlates with patient death at three \( (p = 9.90 \times 10^{-6}) \) and five \( (p = 1.02 \times 10^{-6}) \) years.

BDP1 mRNA expression correlates with ER and PR receptor expression in patients with metastatic breast cancer occurring three-year post-diagnosis (Figure 4A), patients with breast cancer recurring three years post initial diagnosis (Figure 4B) and correlated with death after three years (Figure 4C) and five years (Figure 4D). Together, the data in Figure 4 suggest BDP1 expression correlates with expression changes to the PR and ER breast cancer biomarkers and clinical outcomes.

Roughly 15% of IBC is characterized by low ER, PR, and HER2 expression and is classified as TNBC [58]. BDP1, PR, and ER expression are significantly decreased in the breast cancer datasets queried and negatively correlate with clinical outcomes, as shown in Figure 4. As a result, we speculated if BDP1 is altered in TNBC. BDP1 copy number is significantly decreased in triple-negative breast cancer, \( p = 1.04 \times 10^{-21}, n = 3785 \) samples across three datasets [40,44,47], as shown in Figure 5A. Approximately 70% of TNBCs have been demonstrated to undergo deletions, including 5q13-14 [51], and BDP1 is located at 5q13.2. BDP1 mRNA expression is decreased in TNBC, \( p = 5.23 \times 10^{-6}, n = 2434 \) samples across three datasets [40,42,43], as shown in Figure 5B. We cannot rule out the possibility that the decreased BDP1 mRNA expression may be due, in part, to the decrease in ER expression. We identified four putative ER binding sites at \( -76, -785, -711, \) and \( -535, p = 0.001 \) [60], in the BDP1 promoter that may regulate BDP1 expression. We did not identify any putative PR binding sites in the BDP1 promoter.

BDP1 mRNA expression is increased by the breast cancer chemotherapeutics doxorubicin \( (13.146\text{-fold increase}; p = 4.43 \times 10^{-4}) \), etoposide \( (9.703\text{-fold increase}; p = 8.15 \times 10^{-4}) \), fluorouracil \( (9.468\text{-fold increase}; p = 0.005) \), and bortezomib \( (1.831\text{-fold increase}; p = 0.002) \) in well-studied breast cancer cell lines [35,36], as shown in Figure 6. Together, the data presented in this study suggest that BDP1 may be a novel target for therapeutic intervention for patients with breast cancer, and larger studies are warranted.

5. Conclusions

Breast cancer accounts for 30% of all new cancer diagnoses in the United States. The most common type of breast cancer is invasive breast cancer. A hallmark trait of breast cancer is uncontrolled cell growth due to genetic alterations. TFIIIB-mediated RNA polymerase III transcription is specifically deregulated in human cancers. The TFIIIB BDP1 subunit is not well characterized in human cancer. The objective of this study was to analyze publicly available clinical cancer datasets to determine if BDP1 alterations correlate with clinical outcomes in available breast cancer datasets. BDP1 copy number and expression negatively correlate with breast cancer outcomes, including stage, grade, and mortality. Specifically, we report that BDP1 copy number \( (n = 1602; p = 8.03 \times 10^{-9}) \) and
mRNA expression (n = 130; p = 0.002) are decreased in patients with invasive ductal carcinoma (IDC). In IDC, BDP1 copy number negatively correlated with high grade (n = 1992; p = 2.62 × 10^{-10}) and advanced stage (n = 1992; p = 0.005). BDP1 mRNA expression negatively correlated in high grade (n = 55; p = 6.81 × 10^{-4}) and advanced stage (n = 593; p = 4.66 × 10^{-4}) IDC. BDP1 mRNA correlates with patient death at three (p = 9.90 × 10^{-6}) and five (p = 1.02 × 10^{-6}) years. Also, BDP1 copy number decreased in TNBC (n = 3786; p = 1.04 × 10^{-21}). Both BDP1 copy number (n = 3785; p = 1.0 × 10^{-14}) and mRNA expression (n = 2434; p = 5.23 × 10^{-6}) are altered in TNBC. Finally, BDP1 mRNA expression is increased by the breast cancer chemotherapeutics doxorubicin (13.146-fold increase; p = 4.43 × 10^{-4}), etoposide (9.703-fold increase; p = 8.15 × 10^{-4}), fluorouracil (9.468-fold increase; p = 0.005), and bortezomib (1.831-fold increase; p = 0.002) in well-studied breast cancer cell lines. Together, the data presented suggest a role for BDP1 alterations in invasive breast cancer.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14071658/s1, Figure S1: BDP1 mRNA expression correlates with substages in breast cancer.

Author Contributions: Conceptualization, L.S.; methodology, S.C.-P. and L.S.; validation, S.C.-P. and L.S.; formal analysis, S.C.-P. and L.S.; investigation, S.C.-P. and L.S.; data curation, S.C.-P. and L.S.; writing—original draft preparation, L.S.; writing—review and editing, S.C.-P. Both authors have read and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The present study used publicly available datasets. Hyperlinks to datasets utilized are provided in Table 1. Data analysis was performed using Oncomine Research Edition, retired on 17 January 2022.

Acknowledgments: We thank St. John’s University for funding this research.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [CrossRef] [PubMed]
2. Akram, M.; Iqbal, M.; Daniyal, M.; Khan, A.U. Awareness and current knowledge of breast cancer. Biol. Res. 2017, 50, 33. [CrossRef] [PubMed]
3. American Cancer Society. How Common is Breast Cancer? Available online: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html (accessed on 2 February 2020).
4. Sharma, G.N.; Dave, R.; Sanadya, J.; Sharma, P.; Sharma, K.K. Various types and management of breast cancer: An overview. J. Adv. Pharm. Technol. Res. 2010, 1, 109–126. [PubMed]
5. Schramm, L.; Hernandez, N. Recruitment of RNA polymerase III to its target promoters. Genes Dev. 2002, 16, 2593–2620. [PubMed]
6. Cabarcas, S.; Schramm, L. RNA polymerase III transcription in cancer: The BRF2 connection. Mol. Cancer 2011, 10, 47. [CrossRef] [PubMed]
7. White, R.J. RNA polymerase III transcription and cancer. Oncogene 2004, 23, 3208–3216. [CrossRef]
8. Schramm, L.; Pendergrast, P.S.; Sun, Y.; Hernandez, N. Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters. Genes Dev. 2000, 14, 2650–2663. [CrossRef]
9. Teichmann, M.; Wang, Z.; Roeder, R.G. A stable complex of a novel transcription factor IIB-related factor, human TFIIIB50, and associated proteins mediate selective transcription by RNA polymerase III of genes with upstream promoter elements. Proc. Natl. Acad. Sci. USA 2000, 97, 14200–14205. [CrossRef]
10. Cairns, C.A.; White, R.J. p53 is a general repressor of RNA polymerase III transcription. EMBO J. 1998, 17, 3112–3123. [CrossRef]
11. Felton-Edkins, Z.A.; Kenneth, N.S.; Brown, T.R.; Daly, N.L.; Gomez-Roman, N.; Grandori, C.; Eisenman, R.N.; White, R.J. Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell Cycle 2003, 2, 181–184. [CrossRef]
12. Cabarcas, S.; Watabe, K.; Schramm, L. Inhibition of U6 snRNA Transcription by PTEN. Online J. Biol. Sci. 2010, 10, 114–125. [CrossRef]
Cancers 2022, 14, 1658

13. Woivode, A.; Johnson, S.A.; Zhong, S.; Zhang, C.; Roeder, R.G.; Teichmann, M.; Johnson, D.L. PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex. Mol. Cell. Biol. 2008, 28, 4204–4214. [CrossRef]

14. Zhao, D.; Lu, X.; Wang, G.; Lan, Z.; Liao, W.; Li, J.; Liang, X.; Chen, J.R.; Shah, S.; Shang, X.; et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 2017, 542, 484–488. [CrossRef]

15. Veras, I.; Rosen, E.M.; Schramm, L. Inhibition of RNA polymerase III transcription by BRCA1. J. Mol. Biol. 2009, 387, 523–531. [CrossRef]

16. Sutcliffe, J.E.; Cairns, C.A.; McLees, A.; Allison, S.J.; Tosh, K.; White, R.J. RNA polymerase III transcription factor IIIB is a target for repression by pocket proteins p107 and p130. Mol. Cell. Biol. 1999, 19, 4235–4241. [CrossRef]

17. Athineos, D.; Marshall, L.; White, R.J.; Regulation of TFIIIB during F9 cell differentiation. BMC Mol. Biol. 2010, 11, 21. [CrossRef]

18. Johnson, S.A.; Dubeau, L.; Kawalek, M.; Dervan, A.; Schönthal, A.H.; Dang, C.V.; Johnson, D.L. Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. Mol. Cell. Biol. 2003, 23, 3043–3051. [CrossRef]

19. Johnson, S.A.; Dubeau, L.; White, R.J.; Johnson, D.L. The TATA-binding protein as a regulator of cellular transformation. Cell Cycle 2003, 2, 442–444. [CrossRef]

20. Johnson, S.A.S.; Lin, J.J.; Walkley, C.J.; Leathers, M.P.; Coarfa, C.; Johnson, D.L. Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer. Oncotarget 2017, 8, 48832–48845. [CrossRef]

21. Bellido, F.; Sowada, N.; Mur, P.; Lázaro, C.; Pons, T.; Valdés-Mas, R.; Pineda, M.; Aiza, G.; Iglesias, S.; Soto, J.L.; et al. Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. Gastroenterology 2018, 154, 181–194.e120. [CrossRef]

22. Cabarcas, S.; Jacob, J.; Veras, I.; Schramm, L. Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells. BMC Mol. Biol. 2008, 9, 74. [CrossRef]

23. Fang, Z.; Yi, Y.; Shi, G.; Li, S.; Chen, S.; Lin, Y.; Li, Z.; He, Z.; Li, W.; Zhong, S. Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer. Mol. Oncol. 2017, 11, 1752–1767. [CrossRef]

24. Huang, C.; Zhang, Y.; Zhong, S. Alcohol Intake and Abnormal Expression of Brf1 in Breast Cancer. Oxid. Med. Cell. Longev. 2019, 2019, 4818106. [CrossRef]

25. Cabarcas-Petroski, S.; Meneses, P.I.; Schramm, L. A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma. BMC Cancer 2020, 20, 1093. [CrossRef]

26. Garcia, M.J.; Pole, J.C.; Chin, S.F.; Teschendorff, A.; Naderi, A.; Ozdag, H.; Vias, M.; Kranjac, T.; Subkhankulova, T.; Paish, C.; et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005, 24, 5235–5245. [CrossRef]

27. Lockwood, W.W.; Chari, R.; Coe, B.P.; Thu, K.L.; Garnis, C.; Malloff, C.A.; Campbell, J.; Williams, A.C.; Brenton, J.D.; Benet, J.; et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med. 2010, 7, e1000315. [CrossRef]

28. Lu, M.; Tian, H.; Yue, W.; Li, L.; Li, S.; Qi, L.; Hu, W.; Gao, C.; Si, L. Overexpression of TFIIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer. Med. Oncol. 2013, 30, 553. [CrossRef]

29. Lu, M.; Tian, H.; Yue, W.; Li, L.; Li, S.; Qi, L.; Hu, W.; Gao, C.; Si, L. TFIIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis. PLoS ONE 2014, 9, e88032. [CrossRef]

30. Melchor, L.; Garcia, M.J.; Honrado, E.; Pole, J.C.; Alvarez, S.; Edwards, P.A.; Caldas, C.; Brenton, J.D.; Benet, J. Genomic analysis of the 8p11-12 amplicon in familial breast cancer. Int. J. Cancer 2007, 120, 714–717. [CrossRef]

31. Tian, Y.; Lu, M.; Yue, W.; Li, L.; Li, S.; Gao, C.; Si, L.; Qi, L.; Hu, W.; Tian, H. TFIIIB-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition. Biomed. Res. Int. 2014, 2014, 530786. [CrossRef]

32. Tian, Y.; Wang, C.; Lu, M. BRF2 as a promising indicator for radical lymph-node dissection surgery in patients with cN0 squamous cell carcinoma of the middle thoracic esophagus. Surg. Today 2019, 49, 158–169. [CrossRef] [PubMed]

33. Son, H.J.; Mo, H.Y.; Yoo, N.J.; Lee, S.H. Somatic mutations of cancer-related genes PELP1 and BDP1 in colorectal cancers. Pathol. Res. Pract. 2020, 216, 153107. [CrossRef] [PubMed]

34. Cabarcas-Petroski, S.; Schramm, L. BDP1 Expression Correlates with Clinical Outcomes in Activated B-Cell Diffuse Large B-Cell Lymphoma. BioMedInformatics 2022, 2, 169–183. [CrossRef]

35. Troester, M.A.; Hoadley, K.A.; Parker, J.S.; Perou, C.M. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environ. Health Perspect. 2004, 112, 1607–1613. [CrossRef]

36. Nickeleit, I.; Zender, S.; Sasse, F.; Geffers, R.; Brandes, G.; Sörensen, I.; Steinmetz, H.; Kubicka, S.; Carlasson, M.; Menche, D.; et al. Argyrin reveals a critical role for the tumor suppressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008, 14, 23–35. [CrossRef]

37. Rhodes, D.R.; Yu, J.; Shanker, K.; Dershpan, N.; Varambally, R.; Ghosh, D.; Barrette, T.; Pandey, A.; Chinnaiyan, A.M. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6, 533–545. [CrossRef]

38. Rhodes, D.R.; Kalyana-Sundaram, S.; Mahavisno, V.; Varambally, R.; Yu, J.; Briggs, B.B.; Barrette, T.R.; Anstet, M.J.; Kincaid-Beal, C.; Kulkarni, P.; et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9, 166–180. [CrossRef]
Cancers 2022, 14, 1658

39. Barretina, J.; Caponigro, G.; Stranksy, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehár, J.; Kryukov, G.V.; Sonkin, D.; et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012, 483, 603–607. [CrossRef]

40. Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012, 486, 346–352. [CrossRef]

41. Efferman, L.J.; Berry, D.A.; Cheang, M.C.; Yau, C.; Perou, C.M.; Carey, L.; DeMichele, A.; Gray, J.W.; Conway-Dorsey, K.; Lemburg, M.E.; et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 Trial. (CALGB 150007/150012; ACRIN 66577). *Breast Cancer Res. Treat.* 2012, 132, 1049–1062. [CrossRef]

42. Kao, K.J.; Chang, K.M.; Hsu, H.C.; Huang, A.T. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. *BMC Cancer* 2011, 11, 143. [CrossRef] [PubMed]

43. Miyake, T.; Nakayama, T.; Naoi, Y.; Yamamoto, N.; Otani, Y.; Kim, S.J.; Shimazu, K.; Shimomura, A.; Maruyama, N.; Tamaki, Y.; et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. *Cancer Sci.* 2012, 103, 913–920. [CrossRef] [PubMed]

44. Nikolsky, Y.; Sviridov, E.; Yao, J.; Dosymbekov, D.; Ustyansky, V.; Kaznacheev, V.; Dezso, Z.; Mulvey, L.; Macconaill, L.E.; Winckler, W.; et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. *Cancer Res.* 2008, 68, 9532–9540. [CrossRef] [PubMed]

45. Deng, M.; Bragelmann, J.; Schultz, J.L.; Perner, S. Web-TCGA: An online platform for integrated analysis of molecular cancer data sets. *BMC Bioinform.* 2016, 17, 72. [CrossRef]

46. Lee, H.; Palm, J.; Grimes, S.M.; Ji, H.P. The Cancer Genome Atlas Clinical Explorer: A web and mobile interface for identifying clinical-genomic driver associations. *Genome Med.* 2015, 7, 112. [CrossRef]

47. Weinstein, J.N.; Collisson, E.A.; Mills, G.B.; Shaw, K.R.; Ozenberger, B.A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J.M.; Network, C.G.A.R. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013, 45, 1113–1120. [CrossRef]

48. van de Vijver, M.J.; He, Y.D.; van’t Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; et al. A gene-expression signature as a predictor of survival in breast cancer. *N. Engl. J. Med.* 2002, 347, 1999–2009. [CrossRef]

49. Kikuchi-Koike, R.; Nagasaka, K.; Tsuda, H.; Ishii, Y.; Sakamoto, M.; Kikuchi, Y.; Fukui, S.; Miyagawa, Y.; Hiraike, H.; Kobayashi, T.; et al. Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. *BMC Cancer* 2019, 19, 521. [CrossRef]

50. Schwendel, A.; Richard, F.; Langreck, H.; Kaufmann, O.; Lage, H.; Winzer, K.J.; Petersen, I.; Dietel, M. Chromosome alternations in breast carcinomas: Frequent involvement of DNA losses including chromosomes 4q and 21q. *Br. J. Cancer* 1998, 78, 806–811. [CrossRef]

51. Hu, X.; Stern, H.M.; Ge, L.; O’Brien, C.; Haydu, L.; Honchell, C.D.; Haverty, P.M.; Peters, B.A.; Wu, T.D.; Amler, L.C.; et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. *Mol. Cancer Res.* 2009, 7, 511–522. [CrossRef]

52. Ginestier, C.; Cervera, N.; Finetti, P.; Esteyries, S.; Esterni, B.; Adélaïde, J.; Xerli, L.; Viens, P.; Jacquemier, J.; Charafe-Jauffret, E.; et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. *Clin. Cancer Res.* 2006, 12, 4533–4544. [CrossRef] [PubMed]

53. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Zhang, Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 2017, 45, W98–W102. [CrossRef]

54. Osborne, C.K. Steroid hormone receptors in breast cancer management. *Breast Cancer Res. Treat.* 1998, 51, 227–238. [CrossRef] [PubMed]

55. Park, P.J.; Schmidt, B.P.; Dupont, W.D.; Wagner, R.K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. *Cancer* 1984, 54, 2237–2242. [CrossRef]

56. Kinne, D.W.; Butler, J.A.; Kimmel, M.; Flehinger, B.J.; Menendez-Botet, C.; Schwartz, M. Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative group. *Arch. Surg.* 1987, 122, 1303–1306. [CrossRef] [PubMed]

57. Purdie, C.A.; Quinlan, P.; Jordan, L.B.; Ashfield, A.; Ogston, S.; Dewar, J.A.; Thompson, A.M. Progesterone receptor expression is an independent prognostic variable in early breast cancer: A population-based study. *Br. J. Cancer* 2014, 110, 565–572. [CrossRef]

58. Abramson, V.G.; Mayer, I.A. Molecular Heterogeneity of Triple Negative Breast Cancer. *Curr. Breast Cancer Rep.* 2014, 6, 154–158. [CrossRef]

59. Bergin, A.R.T.; Loi, S. Triple-negative breast cancer: Recent treatment advances. *F1000Research* 2019, 8, 1342. [CrossRef]

60. Dreo, R.; Ambrosini, G.; Groux, R.; Cavin Périer, R.; Bucher, P. The eukaryotic promoter database in its 30th year: Focus on non-vertebrate organisms. *Nucleic Acids Res.* 2017, 45, D51–D55. [CrossRef]

61. Das, S.; Tripathi, N.; Siddharth, S.; Nayak, A.; Nayak, D.; Sethy, C.; Bharatam, P.V.; Kundu, C.N. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL–DR5 axis. *Apoptosis* 2017, 22, 1205–1224. [CrossRef]

62. Takahashi, K.; Tanaka, M.; Inagaki, A.; Wanihuchi, H.; Izumi, Y.; Miura, K.; Nagayama, K.; Shiota, M.; Iwao, H. Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. *Int. J. Oncol.* 2013, 43, 1985–1991. [CrossRef] [PubMed]

63. Tseng, L.M.; Liu, C.Y.; Chang, K.C.; Chu, P.Y.; Shiu, C.W.; Chen, K.F. CIP2A is a target of bortezomib in human triple negative breast cancer cells. *Breast Cancer Res.* 2012, 14, R68. [CrossRef] [PubMed]
64. Thorn, C.F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T.E.; Altman, R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet. Genom. 2011, 21, 440–446. [CrossRef] [PubMed]

65. Denard, B.; Jiang, S.; Peng, Y.; Ye, J. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy. BMC Cancer 2018, 18, 813. [CrossRef] [PubMed]

66. Gouge, J.; Guthertz, N.; Kramm, K.; Dergai, O.; Abascal-Palacios, G.; Satia, K.; Cousin, P.; Hernandez, N.; Grohmann, D.; Vannini, A. Molecular mechanisms of Bdp1 in TFIIIB assembly and RNA polymerase III transcription initiation. Nat. Commun. 2017, 8, 130. [CrossRef]

67. Li, X.; Sun, L.; Stucky, A.; Tu, L.; Cai, J.; Chen, X.; Wu, Z.; Jiang, X.; Li, S.C. Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364. [CrossRef]